Salivary gland toxicity from radiopharmaceutical therapy—particularly from alpha-emitting therapies like 225Ac-PSMA—is a critical dose-limiting side effect, often leading to debilitating dry mouth. Prior attempts to alleviate dry mouth using cold packs, single anticholinergics, or external cooling have shown minimal protective benefit. A dual-protective approach using botulinum toxin (Botox) alongside an anti-nausea patch significantly reduces salivary gland toxicity in patients with metastatic prostate cancer undergoing PSMA-targeted radiopharmaceutical therapy. The strategy led to a 30% decrease in PSMA uptake by the salivary glands without affecting the treatment's cancer-fighting efficacy. This reduction may enhance treatment adherence and improve overall patient outcomes. "In order...